N. Schooler

667 total citations
18 papers, 517 citations indexed

About

N. Schooler is a scholar working on Psychiatry and Mental health, Clinical Psychology and Cognitive Neuroscience. According to data from OpenAlex, N. Schooler has authored 18 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Psychiatry and Mental health, 3 papers in Clinical Psychology and 3 papers in Cognitive Neuroscience. Recurrent topics in N. Schooler's work include Schizophrenia research and treatment (12 papers), Receptor Mechanisms and Signaling (2 papers) and Functional Brain Connectivity Studies (2 papers). N. Schooler is often cited by papers focused on Schizophrenia research and treatment (12 papers), Receptor Mechanisms and Signaling (2 papers) and Functional Brain Connectivity Studies (2 papers). N. Schooler collaborates with scholars based in United States and Czechia. N. Schooler's co-authors include Jonathan Levine, John M. Kane, Daniel Umbricht, Donna Ames, Michael Borenstein, José Alvir, J.A. Lieberman, John Rotrosen, Moran Rubinstein and Margaret G. Woerner and has published in prestigious journals such as Biological Psychiatry, Schizophrenia Research and Journal of Clinical Psychopharmacology.

In The Last Decade

N. Schooler

18 papers receiving 500 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. Schooler United States 8 252 132 115 80 71 18 517
H. M. Emrich Germany 13 215 0.9× 80 0.6× 86 0.7× 77 1.0× 33 0.5× 27 542
W. Alexander Morton United States 10 331 1.3× 119 0.9× 110 1.0× 41 0.5× 60 0.8× 13 595
Christian Barnas Austria 13 230 0.9× 70 0.5× 101 0.9× 43 0.5× 78 1.1× 25 515
Donald R. Kanter United States 13 354 1.4× 109 0.8× 124 1.1× 56 0.7× 42 0.6× 17 631
Eugene H. Makela United States 12 225 0.9× 70 0.5× 84 0.7× 72 0.9× 56 0.8× 21 529
Mary Ann Knesevich United States 9 261 1.0× 122 0.9× 77 0.7× 96 1.2× 85 1.2× 13 576
S. De Risio Italy 16 137 0.5× 158 1.2× 157 1.4× 58 0.7× 173 2.4× 26 625
Ballenger Jc United States 15 327 1.3× 99 0.8× 109 0.9× 40 0.5× 135 1.9× 19 650
R T Owen United Kingdom 8 210 0.8× 110 0.8× 121 1.1× 40 0.5× 178 2.5× 9 583
Riccardo Guglielmo Italy 13 166 0.7× 138 1.0× 144 1.3× 78 1.0× 126 1.8× 29 601

Countries citing papers authored by N. Schooler

Since Specialization
Citations

This map shows the geographic impact of N. Schooler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Schooler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Schooler more than expected).

Fields of papers citing papers by N. Schooler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Schooler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Schooler. The network helps show where N. Schooler may publish in the future.

Co-authorship network of co-authors of N. Schooler

This figure shows the co-authorship network connecting the top 25 collaborators of N. Schooler. A scholar is included among the top collaborators of N. Schooler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Schooler. N. Schooler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Fu, Dong‐Jing, Larry Alphs, J.P. Lindenmayer, et al.. (2014). P.3.d.023 Paliperidone palmitate long-acting injectable delays psychotic and mood symptom relapse in schizoaffective disorder. European Neuropsychopharmacology. 24. S534–S535. 1 indexed citations
2.
Schooler, N., Michael Davidson, & Lili C. Kopala. (2003). P.2.132 Reduced relapse rates in recent onset schizophrenia patients treated with risperidone vs. haloperidol. European Neuropsychopharmacology. 13. S337–S337. 4 indexed citations
3.
Marder, S.R., N. Schooler, John M. Kane, et al.. (2003). Tolerability of clozapine and risperidone during a twenty nine week trial. Schizophrenia Research. 60(1). 293–294. 3 indexed citations
4.
Schooler, N., S.R. Marder, John M. Kane, et al.. (2003). Clozapine and risperidone in moderately refractory schizophrenia: A six month double-blind comparison. Schizophrenia Research. 60(1). 302–302. 1 indexed citations
5.
Davidson, Michael, N. Schooler, & Jonathan Rabinowitz. (2003). P.2.124 Treatment of cognitive impairment in recent onset psychosis; a comparison of risperidone and haloperidol. European Neuropsychopharmacology. 13. S334–S334. 1 indexed citations
6.
Goldman, R.S., John A. Bates, Robert M. Bilder, et al.. (1996). The effects of clozapine and haldol on memory functioning in treatment refractory schizophrenics. Schizophrenia Research. 18(2-3). 221–221. 4 indexed citations
7.
Kane, John M., N. Schooler, Stephen R. Marder, et al.. (1996). Efficacy of clozapine versus haloperidol in a long-term clinical trial. Schizophrenia Research. 18(2-3). 127–127. 10 indexed citations
8.
Baker, Robert W., et al.. (1996). Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.. PubMed. 32(1). 89–93. 40 indexed citations
9.
Schooler, N., John M. Kane, Stephen R. Marder, et al.. (1995). Efficacy of clozapine vs haloperidol in a long term clinical trial: Preliminary findings. Schizophrenia Research. 15(1-2). 165–165. 10 indexed citations
10.
Barch, Deanna M., et al.. (1995). A cognitive neuropsychological study of schizophrenia symptoms: Correlates of stroop and semantic priming performance. Schizophrenia Research. 15(1-2). 111–112. 4 indexed citations
11.
Ames, Donna, William C. Wirshing, John M. Kane, et al.. (1995). Efficacy of clozapine vs. haloperidol in a long-term clinical trial: Preliminary results. Biological Psychiatry. 37(9). 661–661. 1 indexed citations
12.
Barch, Deanna M., et al.. (1995). Attention, semantic processing, and symptoms in schizophrenia. Biological Psychiatry. 37(9). 638–638. 2 indexed citations
13.
Kane, John M., et al.. (1993). A one-year comparison of four dosages of haloperidol decanoate. Schizophrenia Research. 9(2-3). 239–240. 13 indexed citations
14.
Schooler, N., et al.. (1993). Treatment strategies in schizophrenia: Effects of dosage reduction and family management on outcome. Schizophrenia Research. 9(2-3). 260–260. 15 indexed citations
15.
Woerner, Margaret G., John M. Kane, J.A. Lieberman, et al.. (1991). The Prevalence of Tardive Dyskinesia. Journal of Clinical Psychopharmacology. 11(1). 34???42–34???42. 103 indexed citations
16.
Schooler, N., et al.. (1989). The influence of family management of patient stabilization. Schizophrenia Research. 2(1-2). 224–224. 6 indexed citations
17.
Levine, Jonathan & N. Schooler. (1986). SAFTEE: a technique for the systematic assessment of side effects in clinical trials.. PubMed. 22(2). 343–81. 288 indexed citations
18.
Levine, Jerrold S. & N. Schooler. (1984). SAFTEE (SYSTEMATIC ASSESSMENT FOR TREATMENT EMERGENT EVENTS). A NEW TECHNIQUE FOR DETECTING SIDE EFFECTS IN CLINICAL TRIALS. Clinical Neuropharmacology. 7. S460–S460. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026